ACADIA Pharmaceuticals (ACAD) News
NASDAQ: ACADHealth CareBiotechnology: Pharmaceutical PreparationsUSD
17.11-0.48 (-2.73%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
ACAD news summary
We found 11 recent headlines mentioning ACADIA Pharmaceuticals (ACAD): 1 in the past week and 5 in the past 30 days, most often from Nasdaq, Business Wire. For price context, ACAD is down 2.73% at $17.11. The most recent story, "Acadia Expands Rett Syndrome Partnership In Japan Through KYORIN Agreement", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest ACADIA Pharmaceuticals headlines
- Acadia Expands Rett Syndrome Partnership In Japan Through KYORIN Agreement(RTTNews) - Acadia Pharmaceuticals Inc. (ACAD) has entered into an exclusive agreement with KYORIN Pharmaceutical (4569.T) to commercialize DAYBUE STIX (trofinetide) in Japan for the treatment of…NasdaqACAD, LEN.B
- Acadia Pharmaceuticals Enters Oversold Territory (ACAD)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a…Nasdaq
- Acadia Pharmaceuticals Reports Third Quarter 2026 Financial ResultsSAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third quarter ended September 30, 2026. “Acadia delivered a strong third quarter,…Business Wire
- Viatris Gears Up to Report Q3 Earnings: Is a Beat in the Cards?VTRS heads into Q3 earnings with new product growth, regional sales trends and supply challenges shaping its outlook.NasdaqVTRS, TGTX, ACAD, IOVA
- Tarsus Names Neera Clase Commercial Chief To Expand XDEMVY Reach And Lead Pipeline Planning(RTTNews) - Wednesday, Tarsus Pharmaceuticals, Inc. (TARS) said it has appointed Neera Clase as Chief Commercial Officer (CCO), effective November 1, 2026.NasdaqABT, ACAD, TARS, BRK.A
- Acadia Pharmaceuticals to Announce Third Quarter 2026 Financial Results on November 4, 2026SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, after the close of the…Business Wire
- Will Auvelity Continue to Aid Axsome's Top-Line Growth in Q3?AXSM's Auvelity sales surged 54.2% to $333 million in the first half of 2026. New indications could further expand its growth potential.NasdaqAXSM, JAZZ, ACAD
- 4 CNS Drug Stocks Worth Watching This World Mental Health DayAXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.NasdaqALKS, NBIX, ACAD, AXSM
- Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqACAD, INCY
- Neurocrine's Ingrezza Sales Keep Growing: Can the Momentum Last?NBIX's Ingrezza sales climb 17% in 1H 2026 as strong volume drives a higher full-year outlook, but pricing risks loom.NasdaqNBIX, TEVA, ACAD
- Stocks Pressured by Weakness in ChipmakersThe S&P 500 Index ($SPX ) (SPY ) today is down -0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.42%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.38%. September E-mini S&P…NasdaqAMAT, SNDK, INTU, DDOG